BLCO Stock Recent News
BLCO LATEST HEADLINES
Bausch + Lomb (BLCO) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of $0.03. This compares to earnings of $0.07 per share a year ago.
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced it has identified the event that led to its recent voluntary recall of intraocular lenses (IOLs) on the enVista platform. Now that the cause and affected lots have been confirmed, the company will return these models to market. “We voluntarily recalled these lenses because patient safety dictates every decision.
Investors interested in stocks from the Medical Services sector have probably already heard of Bausch + Lomb (BLCO) and Danaher (DHR). But which of these two stocks presents investors with the better value opportunity right now?
Bausch + Lomb (BLCO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NEW YORK CITY, NY / ACCESS Newswire / April 11, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Bausch + Lomb ("Bausch & Lomb" or "the Company") (NYSE:BLCO). Investors who purchased Bausch & Lomb securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/BLCO.
Bausch + Lomb (BLCO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
NEW YORK CITY, NY / ACCESS Newswire / April 10, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Bausch + Lomb ("Bausch & Lomb" or "the Company") (NYSE:BLCO). Investors who purchased Bausch & Lomb securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/BLCO.
NEW YORK CITY, NY / ACCESS Newswire / April 9, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Bausch + Lomb ("Bausch & Lomb" or "the Company") (NYSE:BLCO). Investors who purchased Bausch & Lomb securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/BLCO.
NEW YORK CITY, NY / ACCESS Newswire / April 8, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Bausch + Lomb ("Bausch & Lomb" or "the Company") (NYSE:BLCO). Investors who purchased Bausch & Lomb securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/BLCO.
NEW YORK CITY, NY / ACCESS Newswire / April 7, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Bausch + Lomb ("Bausch & Lomb" or "the Company") (NYSE:BLCO). Investors who purchased Bausch & Lomb securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/BLCO.